

DIMERIX INVESTOR WEBINAR AND PRESENTATION

MELBOURNE, Australia, 05 October 2023: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar to be held Thursday 5th October 2023 at 11am (AEDT), following its licensing agreement with ADVANZ PHARMA announced today.

Investor Webinar 11:00am AEDT Thursday 5 October

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_ehGibiwsR9SvIXLawfHHyA

Participants may submit questions at registration or during the session

The presentation is attached to this announcement.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster

Dimerix Limited

Chief Executive Officer & Managing Director

Tel: +61 1300 813 321

E: investor@dimerix.com

Rudi Michelson

Monsoon Communications

Tel: +61 3 9620 3333

Mob: +61 (0)411 402 737

E: rudim@monsoon.com.au

Follow us on [LinkedIn](#) and [Twitter](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX 200

DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to any exclusivity period that may apply in key territories. In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease.

About FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.¹ For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.² At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are limited.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,¹ and worldwide about 220,000.³ The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year.⁴ Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

- 1 Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: <https://www.ncbi.nlm.nih.gov/books/NBK532272/>
- 2 Front. Immunol., (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>
- 3 Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; <https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market;>
- 4 Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online <https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/>



Investor Update

October 2023

Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs



Authorised for lodgement by the Board of the Company

Forward looking statements



This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

ADVANZ PHARMA – Leadership in rare disease medicines

ADVANZ PHARMA makes the ideal commercial partner for Dimerix

ADVANZ PHARMA is a global pharmaceutical company and a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia

- **Direct presence** in Europe, Canada, and Australia with at scale rare disease commercial, medical, and market access capabilities



- **Highly experienced team** to deliver marketing, sales, market access, launch and commercial excellence across Europe, Canada and Australia



- **Exceptional knowledge of the specialty and hospital markets** and reimbursement systems across the territories



- **Positive track-record of launching products** and navigating through national/regional/local market access rules and regulations in Europe, Canada and Australia



- **Significant financial resources** and backing by Nordic Capital for investments in growth



Dimerix / **ADVANZ** PHARMA - a strategic partnership



“We are committed to bring innovative rare disease medicines to market which serve a high unmet patient need”



“We are excited to announce this partnership with Dimerix, which is aligned with our strategy to be a partner of choice for the commercialisation of specialty, hospital, & rare disease medicines in Europe, Canada, & Australia”

Steffen Wagner – CEO, ADVANZ PHARMA



“We now have access to Advanz’ broad range of capabilities in the licensed territories, putting us in a far stronger position to work towards bringing our exciting drug candidate, DMX-200 to those FSGS patients with limited treatment options”



“Importantly, this partnership has secured significant value of our asset in EU, UK, Canada and ANZ, whilst enabling Dimerix to retain future value in all other territories”

Dr Nina Webster – CEO & Managing Director, Dimerix

Key elements of **ADVANZ** PHARMA partnership

ADVANZ PHARMA acquires exclusive license to commercialise DMX-200 in European Economic Area, Switzerland, UK, Australia, New Zealand and Canada

Dimerix to receive up to ~AU\$230* million in upfront and milestone payments, plus royalties

- €6.5 million in upfront payment (~AU\$10.8 million) – within 30 days
- up to €132.5 million (~AU\$219 million) in potential milestones
- Tiered royalties on net sales

Dimerix will continue to fund and execute the global ACTION3 Phase 3 study for DMX-200 in FSGS patients

Advanz will be responsible for submission and maintenance of the regulatory dossier in the licensed territories, as well as all sales and marketing activities

Dimerix retains all rights to DMX-200 in all other territories

A new era for Dimerix



- Embarking on a new phase of commercial growth following many years of hard work developing and advancing DMX-200 in kidney disease




- Partnering discussion ongoing in other territories



- Licensing deal marks the first of potentially several agreements globally


Global partnering availability



 Licensed territories (European Economic Area, Switzerland, UK, Canada, Australia, New Zealand) – DMX-200

 Available for licensing -  **QYTOVRA**
[REPA GERMANIUM]

Forecast FSGS market size



FSGS 7MM market size estimated to be

US\$3b p.a¹

- ▶ Current market specifically for FSGS does not exist
- ▶ DMX-200 is the only drug candidate specifically in Phase 3 development for primary FSGS


Forecast FSGS Market Size		
Region	Estimated diagnosed patients (2022)	\$US p.a (2032)
US	85,342 ¹	US\$2.05 billion ¹
EU/UK	85,014 ¹	US\$990 million ¹
Japan	32,644 ¹	US\$225 million ¹
China	>100,000 ⁴	US\$2.8 billion ³

} 7 major markets (MM)

ACTION3 Phase 3 clinical trial

FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB




See: <https://dimerix.com/wp-content/uploads/2022/12/FINAL-ACTION3-pivotal-Phase-3-study-assessing-the-CCR2-inhibitor-DMX-200-in-patients-with-focal-segmental-glomerulosclerosis.pdf>

ACTION3

FSGS CLINICAL STUDY

Part 1 analysis set for March 2024

- Announcement of Part 1 analysis of Phase 3 trial expected on, or around, 15 March 2024*
- A successful outcome would see the Company announce a clinically and statistical meaningful improvement in proteinuria vs placebo and the trial is continuing to Part 2



Late stage, phase 3 clinical development asset





A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.



SCAN ME

Dimerix HQ

425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com